Fingerprint
Dive into the research topics of 'Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005)'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically